Day: March 7, 2024

4th & Heart is the #1 Ghee Butter Brand in the US NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) — Aterian, Inc. (Nasdaq: ATER) (“Aterian” or the “Company”) today announced the recent closing of a strategic minority equity investment in 4th & Heart, the leading U.S. maker of premium ghee butter products. The Company invested approximately $0.2 million in cash and approximately 145,000 shares of Aterian common stock. No other terms of the transaction were disclosed. “We are excited to announce our participation in 4th & Heart’s funding round and we look forward to exploring potential strategic opportunities between our two companies,” said Joe Risico, Aterian’s Co-CEO. “Like our Squatty Potty brand, we see a lot of value in partnering and investing in brands that offer consumers the opportunity to live a healthier,...

NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted an equity award on March 2, 2024, to a newly-hired, non-executive employee. The inducement grant was approved by the Company’s independent Compensation Committee and was made as a material inducement to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grant consists of a non-qualified stock option to purchase an aggregate of 30,000 shares of the Company’s common stock with a 10-year term and an exercise price of $25.75 per share. The option vests as to 25%...

BOSTON, March 07, 2024 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Wednesday, March 13, 2024 at 8:40 AM EST at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida, where members of management will also host investor one-on-one meetings. A live webcast and replay of the presentation will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently...

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) — Golden Star Acquisition Corporation (NASDAQ: GODN) (the “Company” or “Golden Star”) announced today that, on March 6, 2024, it filed a supplement (the “Supplement”) to the definitive proxy statement dated February 7, 2024 (together with the additional proxy statement supplements and annexes, the “Proxy Statement”) with the U.S. Securities and Exchange Commission (the “Commission”), to amend the monthly fee payable by the sponsor of the Company and/or its designee into the trust account to extend the date by which the Company must consummate its initial business combination as proposed in the original Proposal 1 to the extraordinary general meeting of shareholders to be held originally on February 27, 2024, from an amount equal to the lesser of (i) $50,000 for all outstanding Public Shares...

Conference call and webcast today at 5:00 p.m. ET LOS ANGELES, March 07, 2024 (GLOBE NEWSWIRE) — FAT (Fresh. Authentic. Tasty.) Brands Inc. (NASDAQ: FAT) (“FAT Brands” or the “Company”) today reported fiscal fourth quarter and full fiscal year 2023 financial results for the fiscal year ended December 31, 2023. “With the acquisition of Smokey Bones early in the fourth quarter, we have grown the FAT Brands portfolio to 18 iconic restaurant brands with annualized system wide sales of $2.5 billion,” said Andy Wiederhorn, Chairman of FAT Brands. “We opened 125 restaurants in 2023, including 29 in the fourth quarter. We are seeing strong franchisee interest in development opportunities, having signed more than 225 development agreements in 2023, bringing our total pipeline to 1,100 units. This represents the potential for over 50% EBITDA...

Bel plans to nominate David Valletta to join the Board, Former Executive Vice President of Worldwide Sales at Vishay Intertechnology WEST ORANGE, N.J., March 07, 2024 (GLOBE NEWSWIRE) — Bel Fuse Inc. (Nasdaq: BELFA and BELFB) (“Bel” or the “Company”), a designer, manufacturer, and provider of products that power, protect and connect electronic circuits, today announced that John Tweedy will retire from the Board and not stand for re-election at the Company’s 2024 Annual Meeting of Shareholders. The Board of Directors plans to nominate David Valletta to join the Board in 2024. Mr. Tweedy has served on Bel’s Board since 1996 and throughout the years has served on various committees including Audit and Executive. John has been instrumental during Bel’s various acquisitions, international expansion, and recent changes to the overall...

New $900M facility provides liquidity and flexibility at greater scale BURLINGTON, Mass., March 07, 2024 (GLOBE NEWSWIRE) —  Progress (NASDAQ: PRGS), the trusted provider of infrastructure software, today announced that it has entered into a Fourth Amended and Restated Credit Agreement (the “Amended Credit Agreement”), which provides a revolving credit facility in an aggregate principal amount of $900 million, and replaces the Company’s existing secured credit facilities. The revolving facilities under the Amended Credit Agreement will mature on March 7, 2029. As of the closing date, the Amended Credit Agreement has no term loan facility and there are no revolving credit loans outstanding.   Progress CFO Anthony Folger stated, “This new credit facility provides more scale and flexibility, both of which are important to support...